Pharvaris (NASDAQ:PHVS – Free Report) had its price objective hoisted by JMP Securities from $46.00 to $55.00 in a research note released on Friday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock.
Pharvaris Trading Down 0.7 %
Shares of NASDAQ:PHVS opened at $17.60 on Friday. Pharvaris has a 1 year low of $15.21 and a 1 year high of $33.00. The firm has a fifty day moving average price of $19.02 and a 200 day moving average price of $19.35.
Hedge Funds Weigh In On Pharvaris
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio bought a new position in shares of Pharvaris in the third quarter worth about $57,000. Barclays PLC bought a new position in Pharvaris in the 3rd quarter worth approximately $106,000. Geode Capital Management LLC increased its position in Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after buying an additional 5,753 shares during the period. HighVista Strategies LLC lifted its holdings in shares of Pharvaris by 35.9% during the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after buying an additional 6,018 shares during the last quarter. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Pharvaris in the fourth quarter worth $196,000.
About Pharvaris
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
- Five stocks we like better than Pharvaris
- What Are Some of the Best Large-Cap Stocks to Buy?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- Financial Services Stocks Investing
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Business Services Stocks Investing
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
